Pazopanib HCl (GW786034 HCl)

Catalog No.S1035

Pazopanib HCl (GW786034 HCl) Chemical Structure

Molecular Weight(MW): 473.98

Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 191 In stock
USD 147 In stock
USD 270 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • IC50 of Pazopanib that block ANDV-induced EC permeability. Endothelial cells were ANDV infected, and 3 days postinfection the permeability of cells in response to VEGF addition was determined in the presence or absence of increasing amounts of kinase inhibitor. (B): VEGFR2-Src inhibitors block ANDV-induced permeability. Endothelial cells were plated on vitronectin-coated Transwell inserts and infected at an MOI of 0.5 in triplicate with ANDV. Three days postinfection, the permeability of ANDV- and mock-infected endothelial cell monolayers was determined at indicated times in the presence or absence of Pazopanib.

    J Virol, 2011, 85(5): 2296-303. Pazopanib HCl (GW786034 HCl) purchased from Selleck.

    MRC5 non-transformed human lung fibroblasts were infected with influenza viruses (100 multiplicity of infection). Two hours after infection the cells were treated with vehicle control; sorafenib tosylate (2mM); pazopanib (2mM); OSU-03012 (2mM); and AR-13 (2mM). Twenty-four hours after infection the cells are treated with live/dead agent where green cells are viable and cells staining yellow or red are considered dead. Cells are examined at 10 magnification in a Hermes wide-field microscope (n¼3 SEM) P<0.05 less than vehicle control level of virus-mediated cell killing.

    J Cell Physiol, 2016, 231(10):2286-302.. Pazopanib HCl (GW786034 HCl) purchased from Selleck.

  • Effect of HDIL-2/TKI on apoptosis of RCC cells. Three RCC cell lines treated with different concentrations of Pazopanib and HDIL-2 and incubated for 48 h. Microscopic images show apoptotic materials 48 h following treatment (arrows show the apoptotic materials in the pazopanib-treated cells).

    Expert Opin Pharmacother 2014 15(11), 1489-99. Pazopanib HCl (GW786034 HCl) purchased from Selleck.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.
Features A multi-kinase inhibitor.
Targets
VEGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
VEGFR3 [1]
(Cell-free assay)
FGFR [1]
(Cell-free assay)
PDGFR [1]
(Cell-free assay)
10 nM 30 nM 47 nM 74 nM 84 nM
In vitro

Pazopanib potently inhibits VEGF-induced phosphorylation of VEGFR2 in HUVEC cells with IC50 of 8 nM. [1] Pazopanib shows dose-dependent growth inhibition in all synovial sarcoma cell lines including SYO-1 and HS-SY-II cells. Proliferation of SYO-1 and HS-SY-II cells is inhibited even at 1 µg/mL of Pazopanib and is completely abolished at 5 µg/mL. Pazopanib induces G1 arrest, and thereby suppresses the growth of synovial sarcoma cells. Phosphorylation of Akts, GSK-3β, JNKs, p70 S6 Kinase, and mTOR is suppressed in Pazopanib-treated SYO-1 cells compared with that in the vehicle-treated cells. [2] Pazopanib between 20 m g/mL and 22.5 m g/mL shows an increasing reduction of RPE cell viability. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HUVEC M1L2bmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MYnpcohq[mm2czD0bIUhXkWJRj3pcoR2[2WmIIDyc4xq\mW{YYTpc44hd2ZiSGXWSWN{ NVyxc2lqOTh4MkCzPFI>
HUVEC M{ntXGtqdmG|ZTDhd5NigQ>? Mk\MbY5pcWKrdIOgWmVITi2rbnT1Z4VlKHCqb4PwbI9zgWyjdHnvckBw\iCYRVfGVk0zKGmwIFjVWmVEKGOnbHzzJJdqfGhiYX6gTWM2OCCxZjFijNw5KG6P M2\wWlE5PjJyM{iy
MM M2rSbGtqdmG|ZTDhd5NigQ>? NGG3coNqdmirYnn0d{BXTUeILXnu[JVk\WRicHjvd5Bpd3K7bHH0bY9vKG:oIH\seFE> MmrmNVcyPjR|M{K=
MM.1S NXfFPVd{T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NWrnWIRTOTBizsznM41N NXnGbIU{cW6qaXLpeJMhVU1iQ3XscEBIem:5dHi= MnPCNVcyPjR|M{K=
MM.1R M3G0dmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M1v6elExKM7:Zz;tUC=> M3v0OYlvcGmkaYTzJG1OKEOnbHygS5Jwf3Sq M2f2ZlE4OTZ2M{Oy
RPMI NUDqcopMT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MWWxNEDPxGdxbVy= MkDlbY5pcWKrdIOgUW0hS2WubDDHdo94fGh? MXGxO|E3PDN|Mh?=
Dox40 MUnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NYjGdWhwOTBizsznM41N MULpcohq[mm2czDNUUBE\WyuIFfyc5d1cA>? NF7I[5kyPzF4NEOzNi=>
INA-6 MWXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NH;SXXcyOCEQvHevcWw> NYDvfGFicW6qaXLpeJMhVU1iQ3XscEBIem:5dHi= M4DhclE4OTZ2M{Oy
OPM2 MU\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NFnwe5cyOCEQvHevcWw> Mn;VbY5pcWKrdIOgUW0hS2WubDDHdo94fGh? MX6xO|E3PDN|Mh?=
U266 NGTiemlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MYKxNEDPxGdxbVy= MlfqbY5pcWKrdIOgUW0hS2WubDDHdo94fGh? Mmm1NVcyPjR|M{K=
MM.1S MkXOZ5l1d3SxeHnjbZR6KGG|c3H5 M1OwOlIxKM7:Zz;tUC=> MkjVbY5pcWKrdIOgUW0hS2WubDDTeZJ3cX[jbB?= Mlr0NVcyPjR|M{K=
MM.1R MV3jfZRwfG:6aXPpeJkh[XO|YYm= NVjOU4h3OjBizsznM41N M{GxO4lvcGmkaYTzJG1OKEOnbHygV5Vzfmm4YXy= MmnENVcyPjR|M{K=
RPMI M3nYWoN6fG:2b4jpZ4l1gSCjc4PhfS=> NFrrcFIzOCEQvHevcWw> MYLpcohq[mm2czDNUUBE\WyuIGP1dpZqfmGu NXrVOWZnOTdzNkSzN|I>
Dox40 M1HTXIN6fG:2b4jpZ4l1gSCjc4PhfS=> NH7vTnUzOCEQvHevcWw> MXzpcohq[mm2czDNUUBE\WyuIGP1dpZqfmGu MWWxO|E3PDN|Mh?=
INA-6 M{nKSYN6fG:2b4jpZ4l1gSCjc4PhfS=> NYLpc|FZOjBizsznM41N NEC1WFZqdmirYnn0d{BOVSCFZXzsJHN2en[rdnHs MVmxO|E3PDN|Mh?=
OPM2 MYXjfZRwfG:6aXPpeJkh[XO|YYm= MoS2NlAh|rypL33M NGDMWXNqdmirYnn0d{BOVSCFZXzsJHN2en[rdnHs MYGxO|E3PDN|Mh?=
U266 NYK5XYl5[3m2b4TvfIlkcXS7IHHzd4F6 MlPqNlAh|rypL33M MofBbY5pcWKrdIOgUW0hS2WubDDTeZJ3cX[jbB?= Ml;wNVcyPjR|M{K=
MM.1S NGDpUZlHfW6ldHnvckBie3OjeR?= MW\zeZBxemW|c3XzJHZGT0ZvSX7keYNm\CCHbnTveIhmdGmjbDDD[YxtKFC{b3zp[oVz[XSrb36gZY5lKE2rZ4LheIlwdi5? Ml33NVcyPjR|M{K=
MM.1R Mn;FSpVv[3Srb36gZZN{[Xl? MoXId5VxeHKnc4Pld{BXTUeILVnu[JVk\WRiRX7kc5Rp\WyrYXygR4VtdCCScn;sbYZmemG2aX;uJIFv\CCPaXfyZZRqd25w M1fke|E4OTZ2M{Oy
Dox40 Mn7ISpVv[3Srb36gZZN{[Xl? NVjtdYwze3WycILld5NmeyCYRVfGMWlv\HWlZXSgSY5ld3SqZXzpZYwhS2WubDDQdo9tcW[ncnH0bY9vKGGwZDDNbYdz[XSrb36u MonHNVcyPjR|M{K=
OPM2 MoWxSpVv[3Srb36gZZN{[Xl? MXHzeZBxemW|c3XzJHZGT0ZvSX7keYNm\CCHbnTveIhmdGmjbDDD[YxtKFC{b3zp[oVz[XSrb36gZY5lKE2rZ4LheIlwdi5? MVqxO|E3PDN|Mh?=
HBMEC NUPnboNKT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MmLYglExKM7:TR?= NH3JdHZFVVOR MmG5TWM2OD1zIN88US=> MX[yNVA5OTZ3Nh?=
HBMEC NX\6cY1DTnWwY4Tpc44h[XO|YYm= MofNglEh|ryP M2\KXWROW09? NIfGTWRi[nKxZ3H0[ZMhfGinIIDoc5NxcG:{eXzheIlwdiCxZjDWSWdHWjJid3n0bEBlcXO{dYD0bY9vKG:oIHTve45{fHKnYX2gVGxE|rNz NEjISmIzOTB6MU[1Oi=>
HBMEC M3j1ZWZ2dmO2aX;uJIF{e2G7 Mn;GglEh|ryP MWrEUXNQ Mlm3[Il{enWydIOgeIhmKFKjcz3SZYYuTVKNIIDheIh4[XlidHjyc5VocCCmZXPy[YF{\WRicHjvd5Bpd3K7bHH0[YQhVUWNMT:yJIFv\CCHUluxM|I> MU[yNVA5OTZ3Nh?=
HBMEC NUDIO29TTnWwY4Tpc44h[XO|YYm= MVz+NlAh|ryP M3TBWGROW09? M37RT4Rqe3K3cITzJFUxLSCxZjD0eYJmKG[xcn3heIlwdiCjdDCxJO69VQ>? MkXvNlExQDF4NU[=
MDA-MB-231 MXPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MVX+NVAh|ryP M{PhZ2ROW09? NUPEeJFJUUN3ME21JO69VQ>? NYX0fXFOOjFyOEG2OVY>
MDA-MB-231 MUXGeY5kfGmxbjDhd5NigQ>? M1;aeVAvPSEQvF2= MkDwSG1UVw>? M4jzdYlvcGmkaYTzJJRp\SCHUluxM|Ihe2mpbnHsbY5oKHCjdHj3ZZk> MVqyNVA5OTZ3Nh?=
MDA-MB-231 MkLRSpVv[3Srb36gZZN{[Xl? M1e3U|Uh|ryP NWL1[YN2TE2VTx?= MYTpcoR2[2W|IHGgZ4VtdC2leXPs[UBienKnc4S= Mo\wNlExQDF4NU[=
J82 NHnEeHpkgXSxdH;4bYNqfHliYYPzZZk> NVi4NnFohjFyIN88US=> M4\MN2ROW09? NFvLT|NKSzVyPUK0MlU4KM7:TR?= M{fEeVIyPTJ7OUCw
T24 M1fDeYN6fG:2b4jpZ4l1gSCjc4PhfS=> MnLXglExKM7:TR?= NInsZ3dFVVOR M1vXRWlEPTB;NUKuOFUh|ryP NFu2R4ozOTV{OUmwNC=>
HT1376 NWnHRoxt[3m2b4TvfIlkcXS7IHHzd4F6 MlPEglExKM7:TR?= MkPBSG1UVw>? NVrrbHlXUUN3ME2yPE4zOSEQvF2= NVrVbo1rOjF3Mkm5NFA>
RT4 MorpZ5l1d3SxeHnjbZR6KGG|c3H5 MWH+NVAh|ryP MX7EUXNQ M4n6bWlEPTB;NT6xOEDPxE1? MWOyNVUzQTlyMB?=
CRL1749 Mn7sZ5l1d3SxeHnjbZR6KGG|c3H5 MkHWglExKM7:TR?= M3K4TWROW09? M1;TPWlEPTB;MkKuOlkh|ryP MmfPNlE2Ojl7MEC=
HTB9 NIXENXhkgXSxdH;4bYNqfHliYYPzZZk> MmeyglExKM7:TR?= M2rrbmROW09? NXvWTJRpUUN3ME2xNU45PCEQvF2= MYmyNVUzQTlyMB?=
Sup MnfHZ5l1d3SxeHnjbZR6KGG|c3H5 NE\0bmN,OTBizszN M3fRbmROW09? NHO3[|BKSzVyPUWzMlMzKM7:TR?= M2DU[VIyPTJ7OUCw
HTB3 MYXjfZRwfG:6aXPpeJkh[XO|YYm= MVn+NVAh|ryP MojTSG1UVw>? MmK2TWM2OD1zND6xOkDPxE1? M{jZbFIyPTJ7OUCw
CEC NYfQW5YxTnWwY4Tpc44h[XO|YYm= MlnsglExKM7:Zz;tUC=> MlW0SG1UVw>? Mnrp[I94di2{ZXf1cIF1\XNiVlXHSkBt\X[nbIO= MWqyNVYzODh{Mh?=
RPE NWHQN5FZTnWwY4Tpc44h[XO|YYm= NYPxUG0xhjFyIN88[{9uVA>? MojuSG1UVw>? NW\4R5Vw\G:5bj3y[Yd2dGG2ZYOgWmVITiCuZY\lcJM> M372WFIyPjJyOEKy
CEC NXnJcYVNTnWwY4Tpc44h[XO|YYm= MXL+OUDPxGdxbVy= MWDEUXNQ NYm4d4N{[myxY3vzJIVv\G:2aHXsbYFtKGOnbHygcYloemG2aX;u MoPjNlE3OjB6MkK=
5637 NXTpfW1qT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NFj5WFlFVVOR M17hVGlEPTB;MUWuNQKBkc7:TR?= M2HxeFI{QDh5NkC1
J82 MlTrS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MoT6SG1UVw>? M2LlfGlEPTB;MUiuOQKBkc7:TR?= MX6yN|g5PzZyNR?=
5637 NWW2OIJsSXW2b4DoZYd6KGG|c3H5 MYGyNEDPxE1? NVfjS4hvTE2VTx?= MYj0dolo\2W{czD0bIUh[XW2b4DoZYdq[yCycn;j[ZN{ M3vXcFI{QDh5NkC1
J82 M2DISmF2fG:yaHHnfUBie3OjeR?= MlfZNlAh|ryP NIPXWXdFVVOR M4XlWpRzcWepZYLzJJRp\SCjdYTvdIhi\2mlIIDyc4Nme3N? MnvSNlM5QDd4MEW=
5637 M{LpWWZ2dmO2aX;uJIF{e2G7 M2rtRVIxKM7:TR?= NVjnVHAzTE2VTx?= M{TlS4lv\HWlZYOgcJl{d3OxbXHsMYRmeGWwZHXueEBv\WO{b4Ppdy=> MnywNlM5QDd4MEW=
J82 M4rwPGZ2dmO2aX;uJIF{e2G7 NXjGcZJzOjBizszN NWewemZ{TE2VTx?= MoL4bY5lfWOnczDsfZNwe2:vYXyt[IVx\W6mZX70JI5m[3Kxc3nz NILzR|kzOzh6N{[wOS=>
5637 NE\SXJVHfW6ldHnvckBie3OjeR?= MWOyNEDPxE1? MULEUXNQ M{jSeIlv\HWlZYOgcJl{d3OxbXWgZYx1\XKjdHnvckBidmRiaX7obYJqfHNiQ1KgZYN1cX[rdIm= Ml;WNlM5QDd4MEW=
J82 NWCwbWNmTnWwY4Tpc44h[XO|YYm= NXLDO3lCOjBizszN M1LFXWROW09? NELWO4FqdmS3Y3XzJIx6e2:|b33lJIFtfGW{YYTpc44h[W6mIHnubIljcXS|IFPCJIFkfGm4aYT5 NV61cIZmOjN6OEe2NFU>
KATO-II M4fNRmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MYC1JO69VQ>? NGHPWmNFVVOR NUTqbm5R[myxY3vzJJBzd2yrZnXyZZRqd25? NWDH[JpiOjV{NEm1OVc>
OCUM-2M M4\BTWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NVzicoFnPSEQvF2= NHXrWlRFVVOR M{nMO4Jtd2OtczDwdo9tcW[ncnH0bY9v NGrzO|MzPTJ2OUW1Oy=>
SNU-16 NVjYb4pKT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NHXFSmo2KM7:TR?= NImxeZBFVVOR NVXCNmx4[myxY3vzJJBzd2yrZnXyZZRqd25? NEnxdmczPTJ2OUW1Oy=>
HSC-39 M2DMcmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MWe1JO69VQ>? NHu0dmNFVVOR M4i1SIJtd2OtczDwdo9tcW[ncnH0bY9v NGT0fGwzPTJ2OUW1Oy=>
KATO-II MULjfZRwfG:6aXPpeJkh[XO|YYm= MoHHglExKM7:TR?= NGLCe5ZFVVOR MmHHTWM2OD1yLkGgeI8hOi5yIN88cY9tN0x? MVeyOVI1QTV3Nx?=
OCUM-2M MVLjfZRwfG:6aXPpeJkh[XO|YYm= M{W0fZ4yOCEQvF2= Mo\2SG1UVw>? NI\FN4JKSzVyPUCuNUB1dyB{LkCg{txud2xxTB?= MnfPNlUzPDl3NUe=
SNU-16 NWH5bZM2[3m2b4TvfIlkcXS7IHHzd4F6 NGfYd3R,OTBizszN MnntSG1UVw>? MWPJR|UxRTBwMTD0c{AzNjBizsztc4wwVA>? NXPxSItrOjV{NEm1OVc>
HSC-39 NWjGOHN4[3m2b4TvfIlkcXS7IHHzd4F6 NITYU49,OTBizszN NFjwe5BFVVOR M360WGlEPTB;MD6xJJRwKDJwMDFOwI1wdC:O NGjuXpQzPTJ2OUW1Oy=>
NIH 3T3 M2rlO2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M{iweZ4yOCEQvF2= MVXEUXNQ MkDIbY5pcWKrdIOgZ4VtdCCpcn;3eIgh[W6mIHPvcI9vgSCob4LtZZRqd25? Mn2yNlUzPDl3NUe=
KATO-III MX3GeY5kfGmxbjDhd5NigQ>? MlnSNUDPxE1? MUfEUXNQ NXOwNlBvcW6mdXPld{Bk\WyuLXP5Z4xmKGG{cnXzeC=> M4f2NlI2OjR7NUW3
OCUM-2M NWrVTY41TnWwY4Tpc44h[XO|YYm= MWSxJO69VQ>? M1z1UWROW09? NIH2SXBqdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0 MmnuNlUzPDl3NUe=
KATO-III NHnqOYlCeG:ydH;zbZMh[XO|YYm= MXSxJO69VQ>? NXPwWYp2TE2VTx?= Mom0bY5lfWOnczDhdI9xfG:|aYO= NYXNT2pTOjV{NEm1OVc>
OCUM-2M MWDBdI9xfG:|aYOgZZN{[Xl? NUXXNYx{OSEQvF2= MYDEUXNQ M3q4PIlv\HWlZYOgZZBweHSxc3nz NVXhdYRyOjV{NEm1OVc>
KATO-III MmDNSpVv[3Srb36gZZN{[Xl? MUSxJO69VQ>? MoXLSG1UVw>? NInLU3VqdmirYnn0d{BHT0[UMjDwbI9{eGixconsZZRqd25iYX7kJIRwf26|dILlZY0he2mpbnHsbY5oKG2xbHXjeYxmew>? MVuyOVI1QTV3Nx?=

... Click to View More Cell Line Experimental Data

In vivo The mice treated with 30 mg/kg or 100 mg/kg Pazopanib reveals a significant decrease in tumor burden compared with the mice treated with vehicle or 10 mg/kg Pazopanib. Treatment with Pazopanib is well-tolerated and there is no significant difference in the body weight among the mice in each group. [2]

Protocol

Kinase Assay:

[1]

+ Expand

Kinase enzyme assays:

VEGFR enzyme assays for VEGGR1, VEGFR2, and VEGFR3 are run in homogeneous time-resolved fluorescence (HTRF) format in 384-well microtiter plates using a purified, baculovirus-expressed glutathione-S-transferase (GST) fusion protein encoding the catalytic c-terminus of human VEGFR receptor kinases 1, 2, or 3. Reactions are initiated by the addition of 10 μL of activated VEGFR2 kinase solution [final concentration, 1 nM enzyme in 0.1 M HEPES, pH 7.5, containing 0.1 mg/mL bovine serum albumin (BSA), 300 μM dithiothreitol (DTT)] to 10 μL substrate solution [final concentration, 360 nM peptide, (biotin-aminohexyl-EEEEYFELVAKKKK-NH2), 75 μM ATP, 10 μM MgCl2], and 1 μL of titrated Pazopanib in DMSO. Plates are incubated at room temperature for 60 min, and then the reaction is quenched by the addition of 20 μL of 100 mM ethylene diamine tetraacetic acid (EDTA). After quenching, 20 μL HTRF reagents (final concentration, 15 nM Streptavidin-linked allophycocyanin, 1 nM Europium-labeled antiphosphotyrosine antibody diluted in 0.1 mg/mL BSA, 0.1 M HEPES, pH 7.5) is added and the plates incubated for a minimum of 10 min. The fluorescence at 665 nM is measured with a Wallac Victor plate reader using a time delay of 50 μs.
Cell Research:

[1]

+ Expand
  • Cell lines: HUVEC cells
  • Concentrations: 0-10 μM
  • Incubation Time: 1 hour
  • Method:

    Phosphorylation of VEGFR2 is assessed in HUVEC stimulated with VEGF. HUVEC are plated in type-I collagen-coated 10 cm plates in Clonetics EGM-MV medium at 1.0-1.5 × 106 cells/plate. After 24 hours, the confluent cells are serum starved overnight by replacing the growth medium with Clonetics EBM medium containing 0.1% BSA, 500 μg/mL hydrocortisone. Cells are treated with Pazopanib at various concentrations for 1 hour, followed by addition of 10 ng/mL VEGF or vehicle for 10 min. Cells are solubilized in lysis buffer. VEGFR2 is immunoprecipitated using antiflk-1 antibody and analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) followed by Western blotting and detection with antiflk-1 or with antiphosphotyrosine (anti-P-tyr-biotin) antibody. The VEGFR2 phosphorylation level is quantified by densitometry and normalized to the total VEGFR2 level.


    (Only for Reference)
Animal Research:

[2]

+ Expand
  • Animal Models: Immunodeficient mice bearing SYO-1 cells
  • Formulation: --
  • Dosages: 0 mg/kg, 10 mg/kg, 30 mg/kg, or 100 mg/kg
  • Administration: Oral administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 17 mg/mL (35.86 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
30% PEG400+0.5% Tween80+5% propylene glycol
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 473.98
Formula

C21H23N7O2S.HCl

CAS No. 635702-64-6
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02300545 Recruiting Sarcoma, Soft Tissue|Soft Tissue Sarcoma Washington University School of Medicine April 8, 2015 Phase 2
NCT00674024 Completed Neoplasms|Lymphoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 7, 2008 Phase 1
NCT01716416 Recruiting Squamous Cell Carcinoma of the Head and Neck Washington University School of Medicine May 31, 2013 Phase 1
NCT01462630 Recruiting Adult Angiosarcoma|Recurrent Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma Fox Chase Cancer Center|National Cancer Institute (NCI) November 3, 2011 Phase 2
NCT01468922 Completed Sarcoma|Stomach Neoplasms|Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 24, 2011 Phase 1
NCT02342600 Not yet recruiting Gastrointestinal Stromal Tumors Sarcoma Alliance for Research through Collaboration|Novartis January 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Related Antibodies

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Pazopanib HCl (GW786034 HCl) | Pazopanib HCl (GW786034 HCl) supplier | purchase Pazopanib HCl (GW786034 HCl) | Pazopanib HCl (GW786034 HCl) cost | Pazopanib HCl (GW786034 HCl) manufacturer | order Pazopanib HCl (GW786034 HCl) | Pazopanib HCl (GW786034 HCl) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID